Loading...

New Geographic Regions And Acquisitions Will Expand Medical Reach

Published
09 Feb 25
Updated
04 Aug 25
AnalystConsensusTarget's Fair Value
CHF 156.91
4.0% undervalued intrinsic discount
04 Sep
CHF 150.60
Loading
1Y
25.1%
7D
4.3%

Author's Valuation

CHF 156.914.0% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on04 Aug 25
Fair value Increased 7.95%

Medacta Group's higher consensus price target reflects improved sentiment driven by a modest increase in net profit margin and a slight decrease in the future P/E ratio, raising fair value estimates from CHF145.35 to CHF153.91. What's in the News Medacta Group will hold its H1 2025 Sales/Trading Statement Call on July 31, 2025.

Shared on01 May 25
Fair value Increased 3.96%

Shared on23 Apr 25
Fair value Decreased 1.67%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Increased 0.45%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 2.75%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 3.26%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Decreased 6.21%

AnalystConsensusTarget has increased shares outstanding growth rate from -0.0% to -0.0%.

Shared on19 Mar 25
Fair value Increased 0.82%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on12 Mar 25
Fair value Increased 4.33%

AnalystConsensusTarget has increased revenue growth from 13.2% to 14.6% and increased shares outstanding growth rate from -0.0% to 0.0%.